<DOC>
	<DOCNO>NCT01899066</DOCNO>
	<brief_summary>This study evaluate clinical efficacy intravitreal injection Ranibizumab ( Lucentis ) together chemotherapy treatment Retinoblastoma compare chemotherapy alone .</brief_summary>
	<brief_title>Efficacy Study Lucentis Treatment Retinoblastoma</brief_title>
	<detailed_description>This study phase II open label interventional case series . Patients retinoblastoma randomize receive chemotherapy without intravitreal ranibizumab dose 0.5mg/0.05 ml . Patients receive ranibizumab via par plana injection monthly basis total duration therapy 6 month . Patients follow 24 month .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Definite characteristic sign retinoblastoma , Group D base Intraocular International Retinoblastoma classify , IIRC . History surgical intervention retinoblastoma study eye . Any previous disease study eye . Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral ) . Previous participation clinical trial ( either eye ) involve anti angiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Efficacy</keyword>
</DOC>